Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.

Singal AK, Fontana RJ.

Aliment Pharmacol Ther. 2012 Mar;35(6):674-89. doi: 10.1111/j.1365-2036.2011.04990.x. Epub 2012 Jan 19.

2.

Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.

Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H.

J Clin Pharmacol. 2014 Feb;54(2):189-200. doi: 10.1002/jcph.181. Epub 2013 Oct 4.

PMID:
24105676
3.

Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.

Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9.

PMID:
23063679
4.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
5.

De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.

Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD.

World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.

6.

Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.

Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S.

Dig Dis Sci. 2012 May;57(5):1358-65. doi: 10.1007/s10620-011-1988-0. Epub 2011 Dec 2.

PMID:
22134785
7.

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.

J Hepatol. 2010 Sep;53(3):449-54. doi: 10.1016/j.jhep.2010.03.020. Epub 2010 May 25.

PMID:
20646776
8.

Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.

Chien RN, Liaw YF.

Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. doi: 10.1016/j.bpg.2008.11.003. Review.

PMID:
19187868
10.

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D.

J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6.

PMID:
21392168
11.

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.

Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z.

Intern Med. 2012;51(12):1509-15. Epub 2012 Jun 15.

12.

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.

Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.

Antivir Ther. 2012;17(4):701-9. doi: 10.3851/IMP2074. Epub 2012 Feb 23.

PMID:
22358132
13.

Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.

Ye XG, Su QM.

World J Gastroenterol. 2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665. Review.

14.

Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.

Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z.

J Clin Pharmacol. 2014 Sep;54(9):959-67. doi: 10.1002/jcph.351. Epub 2014 Jul 18.

PMID:
24964070
15.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270
16.

[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].

Buti M.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 7:32-8. Review. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Dec;26(10):675.

PMID:
19100229
17.
18.

Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.

Kim SS, Cheong JY, Lee D, Lee MH, Hong SP, Kim SO, Cho SW.

J Med Virol. 2012 Jan;84(1):18-25. doi: 10.1002/jmv.22227. Epub 2011 Oct 25.

PMID:
22028068
19.

Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.

Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS.

Antimicrob Agents Chemother. 2014 Nov;58(11):6710-6. doi: 10.1128/AAC.03845-14. Epub 2014 Aug 25.

20.

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F.

J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.

PMID:
23742912

Supplemental Content

Support Center